Ankerstar Wealth’s ADMA Biologics ADMA Stock Holding History

Ankerstar Wealth’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21	Closed	-$189	–	990
2026 Q1	$189	Sell	21 -15	-42%	-$237	﹤0.01%	857
2025 Q4	$657	Buy	+36	New	+$607	﹤0.01%	566

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Ankerstar Wealth's ADMA Position: Q2 2026 in Review

Ankerstar Wealth sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 21 shares — an estimated $189 sold.

Ankerstar Wealth first reported a position in ADMA in Q4 2025 and held it in 2 quarters. The position peaked at $657 in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Ankerstar Wealth reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
Ankerstar Wealth sold 21 ADMA Biologics shares in Q2 2026, an estimated $189.
Ankerstar Wealth first reported a position in ADMA Biologics in Q4 2025 and held it in 2 quarters.
Ankerstar Wealth's ADMA Biologics position peaked at $657 in Q4 2025.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Ankerstar Wealth's 13F filing for Q2 2026, filed 13 Aug 2026.